trimopan (suspension)
pinewood laboratories ltd, - trimethoprim - oral suspension - 50 mg/5ml
trimopan tablets 20 milligram
berk pharmaceuticals limited - trimethoprim - tablets - 20 milligram
trimopan tablets 100 milligram
pinewood laboratories ltd, - trimethoprim - tablets - 100 milligram
trimopan tablets 200 milligram
pinewood laboratories ltd, - trimethoprim - tablets - 200 milligram
trimopan 100mg tablets
teva uk ltd - trimethoprim - oral tablet - 100mg
trimopan 200mg tablets
teva uk ltd - trimethoprim - oral tablet - 200mg
riopan plus suspension
whitehall-robins inc. - magaldrate; dimethicone - suspension - 96mg; 4mg - magaldrate 96mg; dimethicone 4mg - antacids and adsorbents
riopan plus oral suspension
bahrain pharmacy - magaldrate, simethicone - oral suspension
ditropan xl- oxybutynin chloride tablet, extended release
physicians total care, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - ditropan xl® (oxybutynin chloride) is a once-daily controlled-release tablet indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ditropan xl® is also indicated in the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ditropan xl® (oxybutynin chloride) is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma and in patients who are at risk for these conditions. ditropan xl® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product.
ditropan xl- oxybutynin chloride tablet, extended release
janssen pharmaceuticals, inc. - oxybutynin chloride (unii: l9f3d9renq) (oxybutynin - unii:k9p6mc7092) - oxybutynin chloride 5 mg - ditropan xl ® (oxybutynin chloride) is a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. ditropan xl ® is also indicated for the treatment of pediatric patients aged 6 years and older with symptoms of detrusor overactivity associated with a neurological condition (e.g., spina bifida). ditropan xl ® is contraindicated in patients with urinary retention, gastric retention and other severe decreased gastrointestinal motility conditions, uncontrolled narrow-angle glaucoma. ditropan xl ® is also contraindicated in patients who have demonstrated hypersensitivity to the drug substance or other components of the product. there have been reports of hypersensitivity reactions, including anaphylaxis and angioedema. risk summary there are no adequate data on ditropan xl ® use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscar